June 30, 2025 03:50 PM EDT

Pfizer ends Phase 2 trial for final Trillium CD47 drug

Max Gelman

Senior Editor

Pfizer has terminated a trial testing the second of two CD47 programs it received from the 2021 buyout of Trillium Therapeutics, marking a setback for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Pfizer ends Phase 2 trial for final Trillium CD47 drug

Max Gelman

Senior Editor

Sign up to read this article for free.

Apple Tree Partners' biotechs 'face imminent collapse' as firm battles Russian investor in court

Supreme Court passes on Oklahoma’s drug middlemen spat

AbbVie bags Capstan’s in vivo CAR-T work with $2.1B buyout deal

Sage plans to lay off almost every employee after inking Supernus deal

CBER chief Prasad suggests Covid vaccine harms may outweigh benefits in 'low-risk populations'

Amgen’s stomach cancer drug boosts survival in Phase 3, but ocular side effects leave questions

Pfiz­er ends Phase 2 tri­al for fi­nal Tril­li­um CD47 drug

Max Gelman

Senior Editor

Sign up to read this article for free.

more like this

Ap­ple Tree Part­ner­s' biotechs 'face im­mi­nent col­lapse' as firm bat­tles Russ­ian in­vestor in court

Supreme Court pass­es on Ok­la­homa’s drug mid­dle­men spat

Ab­b­Vie bags Cap­stan’s in vi­vo CAR-T work with $2.1B buy­out deal

Sage plans to lay off al­most every em­ploy­ee af­ter ink­ing Su­per­nus deal

CBER chief Prasad sug­gests Covid vac­cine harms may out­weigh ben­e­fits in 'low-risk pop­u­la­tion­s'

Am­gen’s stom­ach can­cer drug boosts sur­vival in Phase 3, but oc­u­lar side ef­fects leave ques­tions

Pfizer ends Phase 2 trial for final Trillium CD47 drug

Apple Tree Partners' biotechs 'face imminent collapse' as firm battles Russian investor in court

Supreme Court passes on Oklahoma’s drug middlemen spat

AbbVie bags Capstan’s in vivo CAR-T work with $2.1B buyout deal

Sage plans to lay off almost every employee after inking Supernus deal

CBER chief Prasad suggests Covid vaccine harms may outweigh benefits in 'low-risk populations'

Amgen’s stomach cancer drug boosts survival in Phase 3, but ocular side effects leave questions